RT Journal Article
SR Electronic
T1 Mutations within the cGMP-binding domain of CNGA1 causing autosomal recessive retinitis pigmentosa in human and animal model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.10.22278420
DO 10.1101/2022.08.10.22278420
A1 Kandaswamy, Surabhi
A1 Zobel, Lena
A1 John, Bina
A1 Santhiya, Sathiyaveedu Thyagarajan
A1 Bogedein, Jacqueline
A1 Przemeck, Gerhard K.H.
A1 Gailus-Durner, Valérie
A1 Fuchs, Helmut
A1 Biel, Martin
A1 de Angelis, Martin Hrabĕ
A1 Graw, Jochen
A1 Michalakis, Stylianos
A1 Amarie, Oana Veronica
YR 2022
UL http://medrxiv.org/content/early/2022/08/12/2022.08.10.22278420.abstract
AB Retinitis pigmentosa is a group of progressive inherited retinal dystrophies that may present clinically as part of a syndromic entity or as an isolated (nonsyndromic) manifestation. In a family suffering from retinitis pigmentosa, we identified a missense variation in CNGA1 affecting the cyclic nucleotide binding domain (CNBD) and characterized a mouse model developed with mutated CNBD. A gene panel analysis comprising 105 known RP genes was used to analyze a family with autosomal-recessive retinitis pigmentosa (arRP) and revealed that CNGA1 was affected. From sperm samples of ENU mutagenesis derived F1 mice, we re-derived a mutant with a Cnga1 mutation. Homozygous mutant mice, developing retinal degeneration, were examined for morphological and functional consequences of the mutation. In the family, we identified a rare CNGA1 variant (NM_001379270.1) c.1525G>A; (p.Gly509Arg), which co-segregated among the affected family members. Homozygous Cnga1 mice harboring a (ENSMUST00000087213.12) c.1526A>G (p.Tyr509Cys) mutation showed progressive degeneration in the retinal photoreceptors from 8 weeks on. This study supports a role for CNGA1 as a disease gene for arRP and provides new insights on the pathobiology of cGMP-binding domain mutations in CNGA1-RP.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by German Academic Exchange Service (DAAD) (Funding no - 91525094) to SK and by German Federal Ministry of Education and Research (Infrafrontier grant 01KX1012) to MHdA and the German Center for Diabetes Research (DZD) (MHdA).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study involving human subjects was approved by the Madras Medical College Institutional Ethical committee review board and all participants have signed a written informed consent when recruited (Approval no - 29022013)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.